Volume : 09, Issue : 08, August – 2022
Title:
19.EFFECT OF MARIJUANA USE FOR PAIN RELIEF IN PATIENTS WITH FIBROMYALGIA
Authors :
Hassan Jamil, Javairia Jamil, Mustafa Javaid, Mohammad Ibrahim, Abdul Hai
Abstract :
There are only a few studies in the literature on the use of cannabis by fibromyalgia patients. Herbal cannabis or marijuana has been used for the treatment of pain for centuries. This is noteworthy that in recent times its use has been mostly outside traditional medicine. In this study, we audit and conducted a review of the studies and patients with confirmed history of fibromyalgia and the effects of marijuana (Medical Cannabis-MC) for the pain relief, was documented and discussed. Despite lingering controversy, the use of botanical cannabis for medicinal purposes represents the revival of a plant with historical significance reemerging in present day health care. MC appears to be a safe and effective alternative for the treatment of fibromyalgia symptoms.
Keywords: Fibromyalgia; Marijuana; Medical Cannabis.
Cite This Article:
Please cite this article in press Hassan Jamil et al, Effect Of Marijuana Use For Pain Relief In Patients With Fibromyalgia., Indo Am. J. P. Sci, 2022; 09(8).
,
Number of Downloads : 10
References:
1. Gostine M, Davis F, Roberts BA, et al. Clinical characterestics of fibromyalgia in a chronic pain syndrome. Pain Pract. 2017.
2. Arnold LM, Fan J, Russell IJ, et al. The fibromyalgia family study. A genome-wide linkage scan study. Arthritis Rheum. 2013;65:1122–1128.
3. Vincent A, Lahr BD, Wolfe F, et al. Prevalence of fibromyalgia: a population based study in Olmsted county, Minnesota, utilizing the Rochester epidemiology project. Arthritis Care Res (Hoboken). 2013;65:786–792.
4. Segura-Jiménez V, Álvarez-Gallardo IC, Carbonell-Baeza A, et al. Fibromyalgia has a larger impact on physical health then on psychological health, yet both are markedly affected: the Al-Ándalus project. Semin Arthritis Rheum. 2015;44:563–570.
5. MacLean AJ, Schwartz TL. Tramadol for the treatment of fibromyalgia. Expert Rev Neurother. 2015;15:469–475.
6. Derry S, Cording M, Wiffen PJ, et al. Pregabalin for pain in fibromyalgia in adults. Cochrane database Sys Rev. 2016;9:CD011790.
7. Kia S, Choy E. Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines. 2017;5.
8. Fiz J, Durán M, Capellà D, et al. Cannabis use in patients with fibromyalgia: effects on symptoms relief and health-Related quality of life. PLoS One. 2011:6:e18440.
9. Piper BJ, Beals ML, Abess AT, et al. Chronic pain patients’ perspectives of medical cannabis. Pain. 2017;158:1373–1379.
10. Walitt B, Klose P, Fitzcharles MA, et al. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev. 2016;7:CD011694.
11. Pertwee RG. Cannabinoid pharmacology: the first 66 years.Br J Pharmacol 2006;147 Suppl:S163–71.2.
12. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C,Goldenberg DL, et al. The American College of Rheumatology1990 criteria for the classification of fibromyalgia: report ofthe Multicenter Criteria Committee. Arthritis Rheum 1990;33:160–72.3.
13. McNally JD, Matheson DA, Bakowsky VS. The epidemiologyof self-reported fibromyalgia in Canada. Chronic Dis Can2006;27:9–16.4.
14. Boomershine CS, Crofford LJ. A symptom-based approach topharmacologic management of fibromyalgia. Nat Rev Rheu-matol 2009;5:191–9.
15. Ste-Marie PA, Fitzcharles MA, Gamsa A, Ware MA, Shir Y. Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1202-8. doi: 10.1002/acr.21732. PMID: 22730275.
16. Erkens JA, Janse AF, Herings RM. Limited use of medicinalcannabis but for labeled indications after legalization. Phar-macoepidemiol Drug Saf 2005;14:821–2
17. Macfarlane G.J., Kronisch C., Dean L.E., Atzeni F., Häuser W., Fluß E., Choy E., Kosek E., Amris K., Branco J., et al. EULAR revised recommendations for the management of fibromyalgia. Ann. Rheum. Dis. 2017;76:318–328.
18. Fitzcharles M.A., Faregh N., Ste-Marie P.A., Shir Y. Opioid use in fibromyalgia is associated with negative health related measures in a prospective cohort study. Pain Res. Treat. 2013;2013:898493.
19. Schleider L.B., Mechoulam R., Lederman V., Hilou M., Lencovsky O., Betzalel O., Shbiro L., Novack V. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur. J. Intern. Med. 2018;49:37–43.
20. Abuhasira R., Schleider L.B., Mechoulam R., Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur. J. Intern. Med. 2018;49:44–50.
21. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006;58:389–462.
22. Sagy I, Bar-Lev Schleider L, Abu-Shakra M, Novack V. Safety and Efficacy of Medical Cannabis in Fibromyalgia. J Clin Med. 2019 Jun 5;8(6):807. doi: 10.3390/jcm8060807. PMID: 31195754; PMCID: PMC6616435.